FinnCap restated their corporate rating on shares of Bioventix (LON:BVXP) in a research report released on Tuesday, November 21st. The brokerage currently has a GBX 2,600 ($34.99) price objective on the biotechnology company’s stock.
Shares of Bioventix (BVXP) traded down GBX 87 ($1.17) on Tuesday, reaching GBX 2,275.50 ($30.63). The company had a trading volume of 2,208 shares, compared to its average volume of 2,218. Bioventix has a twelve month low of GBX 26.51 ($0.36) and a twelve month high of GBX 2,950 ($39.70).
The business also recently disclosed a dividend, which was paid on Friday, November 10th. Investors of record on Thursday, October 26th were issued a dividend of GBX 71 ($0.96) per share. This is a boost from Bioventix’s previous dividend of $20.00. The ex-dividend date of this dividend was Thursday, October 26th. This represents a yield of 2.67%.
COPYRIGHT VIOLATION WARNING: “Bioventix (LON:BVXP) Earns Corporate Rating from FinnCap” was reported by Week Herald and is the property of of Week Herald. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://weekherald.com/2017/12/10/finncap-reiterates-corporate-rating-for-bioventix-plc-bvxp.html.
Bioventix Company Profile
Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.
Receive News & Ratings for Bioventix PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix PLC and related companies with MarketBeat.com's FREE daily email newsletter.